Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp342 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Bone mineral density in statin users: analysis of a population-based cohort from Spain

Hernandez Jose L , Olmos Jose M , Romana Galo , Martinez Josefina , Yezerska Irina , de Juan Julia , Gonzalez-Macias Jesus

Objective: To analyze the effects of statins on bone mineral density (BMD), in participants from a large population-based cohort.Subjects and methods: We studied 2315 subjects (1422 women and 893 men) from the Camargo Cohort, and analyzed the differences in BMD between statin or non-statin users. We also studied the effect of the type of statin, dose, pharmacokinetic properties, and length of treatment, on BMD.Results: Four hundred...

ba0001pp453 | Osteoporosis: treatment | ECTS2013

Factors influencing levels of bone resorption during denosumab dosing

Eastell Richard , Siris Ethel , Roux Christian , Black Dennis M. , Franchimont Nathalie , Jang Graham , Daizadeh Nadia , Wagman Rachel B. , Austin Matt

Denosumab treatment is associated with low fracture incidence, sustained BMD increases, and reduced sCTX. The decrease in median sCTX is at the quantifiable limit (0.049 ng/ml) one month post-dose, remains low, and attenuates at the end of the 6-month dosing interval. Using 7 years of data from the FREEDOM study and its extension, we characterized changes in sCTX over time and the influencing factors. In the bone turnover marker and pharmacokinetic substudies, serum was collec...

ba0002p21 | (1) | ICCBH2013

Bone disease in children with geroderma osteodysplasticum: a 25-year experience from a single tertiary centre

Gopal-Kothandapani J S , Padidela R , Clayton-Smith J , Chandler K E , Adams J E , Freemont A J , Mughal M Z

Geroderma osteodysplasticum (GO) is a rare autosomal recessive connective tissue disorder characterised by progeria like facies, wrinkled lax skin, joint hypermobility, congenital dislocation of hips and propensity to fragility fractures. In the past 25 years, five patients (three females and two males) diagnosed with GO were referred to our Paediatric metabolic bone service for assessment and management of secondary bone problems. All five children were born to consanguineous...

ba0002p97 | (1) | ICCBH2013

Vitamin D status and bone health in survivors of childhood lymphoblastic leukemia

Schundeln Michael M , Hauffa Pia K , Goretzki Sara C , Lahner Harald , Marschke Laura , Eggert Angelika , Hauffa Berthold P , Grasemann Corinna

Introduction: Lymphoblastic leukemia is the predominant form of childhood malignancies with survival rates of >80%. Late effects of cancer and treatment can affect endocrine function and may account for acute and chronic impairment of bone health.Aim and design: To assess bone health in pediatric patients after therapy for lymphoblastic leukemia we initiated a clinical trial investigating clinical and biochemical parameters of growth, puberty, bone t...

ba0003pp17 | Bone biomechanics and quality | ECTS2014

Bone fragility and matrix hypermineralization is rescued in homozygous OI Brtl mice mutants

Fratzl-Zelman Nadja , Kozloff Kenneth M , Meganck Jeff , Reich Adi , Roschger Paul , Cabral Wayne , Klaushofer Klaus , Marini Joan

Classical osteogenesis imperfecta (OI) is caused by mutations in the two genes encoding type I collagen. OI is associated with low bone mass and abnormally high bone matrix mineralization. The Brtl/+ OI mouse is a knock-in model caused by a glycine substitution in one COL1A1 allele. Brtl/+ pups display 30% perinatal lethality; survivors have small size and brittle bone. Unexpectedly, homozygous Brtl/Brtl pups, producing only mutant collagen, have normal survival rates...

ba0003pp92 | Bone development/growth and fracture repair | ECTS2014

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

Bilezikian John P , Maruani Gerard , Rothman Jeffrey , Clarke Bart L , Mannstadt Michael , Vokes Tamara , Lagast Hjalmar , Shoback Dolores M

Hypoparathyroidism results in low bone turnover and increased bone mineral density (BMD). Replacing deficient PTH with rhPTH(1–84) has the potential to correct these skeletal abnormalities. To investigate the effect of rhPTH(1–84) on BMD and bone turnover markers (BTMs), data from two studies were assessed.REPLACE, a double-blind, multicenter, placebo-controlled study, randomized 134 patients with hypoparathyroidism to receive once-daily rhPTH(...

ba0003lb2 | (1) | ECTS2014

Bisphosphonates for osteoporosis and risk of breast cancer: misleading results from observational studies

Cummings Steven R , Hue Trisha , Cauley Jane A , Bauer Doug C , Ensrud Kristine E , Barrett-Connor Elizabeth , Black Dennis M

Purpose: To test whether bisphosphonates for osteoporosis reduce the risk of breast cancer.Background: Observational studies and meta-analyses find that women taking bisphosphonates have about a 1/3rd reduction in risk of breast cancer as soon as 1 year of treatment. This is plausible because bisphosphonates have in vitro anti-tumor activity and high doses of zoledronate reduce recurrence in women with breast cancer. However, observational studi...

ba0004p105 | (1) | ICCBH2015

Refractory hypercalcaemia of malignancy: responsiveness to Denosumab and Zoledronate

Giri Dinesh , Ramakrishnan Renuka , Hayden James , Brook Lynda , Das Urmi , Mughal M Zulf , Selby Peter , Dharmaraj Poonam , Senniappan Senthil

Background: Hypercalcaemia secondary to malignancy is rare in children and adolescents. Parathyroid hormone related peptide (PTH-rP) secreted by malignant cells increases bone resorption and renal calcium retention causing hypercalcaemia. We report two cases of hypercalcaemia of malignancy refractory to treatment with pamidronate and corticosteroids but responsive to treatment with Denosumab and Zoledronic acid.Case 1: Presenting problem: A 17-year-old b...

ba0004p199 | (1) | ICCBH2015

LRP5-associated high bone mass disorder: novel familial mutation in LRP5 and investigation of bone mineralization density distribution (BMDD)

Roetzer Katharina M , Uyanik Goekhan , Brehm Attila , Zwerina Jochen , Zandieh Shahin , Czech Thomas , Roschger Paul , Klaushofer Klaus

Mutations in LRP5 cause a variety of phenotypes, including high bone mass and low bone mass disorders. In patients with high bone mass, different heterozygous mutations have been described, all of them clustering in a region including the binding pocket for DKK1 and sclerostin. The pathogenic mechanism is thought to be a gain-of-function mediated by an impaired inhibition of the canonical Wnt signalling pathway, thereby leading to increased bone modelling.<p class="abstext...